 |
Business Wire - June 8, 2005
"I'm very excited at the prospect of joining Nanoviricide," Dr. Menon noted, "this technology represents, in my opinion, a market leading concept. It allows for a textbook finish for so many well conceived APIs, allowing delivery to target cells with lowest dosage, which increases efficacy and reduces toxicity." Dr. Menon returned from a trip to Singapore, where he was a keynote speaker at the drug delivery summit.
The Company plans to begin its animal trials this summer on the first of its targeted anti-viral nanoviricides(TM). Dr. Krisna Menon, Chief Regulatory Officer will be supervising and monitoring the animal studies.
Dr. Menon is a well known Pharmaceutical Scientist and Executive. He was awarded the Employee of the Year, Presidents Award (1999) at Eli Lilly, where he was a co-inventor of two drugs GEMZAR and ALIMTA which account for nearly one billion dollars in annual sales. Prior to that, he was Senior Research Scientist at Bayer. At present, he is on the board of directors of KARD Scientific, MA, and Biological Supplies, NY, and scientific advisor to Nexus Pharmaceuticals.
He is the holder of 7 US patents. Dr. Menon received a PhD from Harvard. While at Harvard, he performed pre-clinical studies on AZT, an important anti-HIV drug.
Nanoviricide, Inc.
Nanoviricide, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. Nanoviricide, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types HIV, HCV, Herpes, Asian (bird) flu and Influenza. A nanoviricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a nanoviricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the nanoviricide(TM) particle, destroying it. The company plans to develop novel nanoviricide(TM) drugs first against HIV, and anticipates that in 2006/2007, it will license a product or products to major pharmaceutical companies.
Forward-Looking Statements
Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management, increased government regulation or the company's failure to integrate its acquired companies to achieve the synergies and efficiencies described in the "Management's Discussion and Analysis" section of the Company's filings with the Securities and Exchange Commission where applicable, which may be revised or supplemented in subsequent reports on SEC Forms 10-QSB and 8-K.
CONTACT: For Edot.com, Inc., Miami
John Flynn, 305-860-3307
or
Eugene Seymour, gene@nanoviricide.com
SOURCE: EDot.com, Inc.
050608
BW050609
Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .